{"id":"warfarin-vka","safety":{"commonSideEffects":[{"rate":"2-4","effect":"Bleeding (major and minor)"},{"rate":"0.3-0.5","effect":"Intracranial hemorrhage"},{"rate":"1-2","effect":"Gastrointestinal bleeding"},{"rate":"0.01-0.1","effect":"Skin necrosis"},{"rate":"1-2","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Warfarin is a vitamin K antagonist (VKA) that works by inhibiting the recycling of vitamin K, which is essential for the gamma-carboxylation of clotting factors II, VII, IX, and X in the liver. This results in the production of inactive clotting factors and a prolonged prothrombin time (PT/INR). The anticoagulant effect develops over several days as existing clotting factors are cleared from circulation.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and preventing blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:04.501Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (DVT/PE) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-myocardial infarction thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT07434661","phase":"PHASE3","title":"Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR","status":"NOT_YET_RECRUITING","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2026-02","conditions":"Valve Disease, Heart, Atrial Fibrillation (AF), Valve Replacement Surgery","enrollment":120},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT06884384","phase":"","title":"DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09-15","conditions":"Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events","enrollment":310},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT06429787","phase":"","title":"Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure","status":"RECRUITING","sponsor":"Octapharma","startDate":"2025-02-14","conditions":"Vitamin K-Dependent Coagulation Defect, Significant Bleeding Risk","enrollment":3574},{"nctId":"NCT02798471","phase":"PHASE3","title":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2017-03-27","conditions":"Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)","enrollment":290},{"nctId":"NCT04062097","phase":"","title":"Registration of Idarucizumab for Patients with IntraCranial Hemorrhage","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2019-09-19","conditions":"Intracranial Hemorrhage","enrollment":104},{"nctId":"NCT04249401","phase":"","title":"Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-01","conditions":"Atrial Fibrillation","enrollment":134897},{"nctId":"NCT04195113","phase":"","title":"Perioperative Anticoagulant Use for Surgery Evaluation Emergency Registry","status":"COMPLETED","sponsor":"McMaster University","startDate":"2019-08-07","conditions":"Atrial Fibrillation, Venous Thromboembolism, Arterial Vascular Disease","enrollment":242},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT02832544","phase":"PHASE3","title":"INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-08-22","conditions":"Rheumatic Heart Disease","enrollment":4565},{"nctId":"NCT02981472","phase":"PHASE2","title":"A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-01-19","conditions":"Thrombosis","enrollment":192},{"nctId":"NCT03942913","phase":"","title":"Prospective Real-world Registry Describing Treatment Regimens","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-10-10","conditions":"Subject Under Anticoagulant","enrollment":573},{"nctId":"NCT03395639","phase":"PHASE3","title":"Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-05-15","conditions":"Cardiac Disease","enrollment":168},{"nctId":"NCT02286414","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":"Atrial Fibrillation","enrollment":159},{"nctId":"NCT02319460","phase":"","title":"An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-04-24","conditions":"Hemorrhage","enrollment":2238},{"nctId":"NCT04099238","phase":"","title":"Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-10-01","conditions":"Atrial Fibrillation","enrollment":3739},{"nctId":"NCT03715725","phase":"","title":"A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.","status":"TERMINATED","sponsor":"Bayer","startDate":"2018-10-31","conditions":"Non-valvular Atrial Fibrillation","enrollment":70000},{"nctId":"NCT04518735","phase":"","title":"Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-01","conditions":"Covid19","enrollment":1707},{"nctId":"NCT03374540","phase":"","title":"Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-12-01","conditions":"Nonvalvular Atrial Fibrillation","enrollment":78517},{"nctId":"NCT03244319","phase":"PHASE3","title":"Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2017-12-01","conditions":"MV(Mitral Valve) Repair","enrollment":220},{"nctId":"NCT02942576","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-03-21","conditions":"Atrial Fibrillation","enrollment":632},{"nctId":"NCT02072434","phase":"PHASE3","title":"Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2014-03-25","conditions":"Atrial Fibrillation","enrollment":2199},{"nctId":"NCT03532724","phase":"","title":"Clinical Outcomes From Patient Self-management of Antivitamin K Treatment","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2017-11-01","conditions":"Self Management of Oral Anticoagulation With VKA Therapy","enrollment":927},{"nctId":"NCT03682419","phase":"NA","title":"Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)","status":"COMPLETED","sponsor":"LumiraDx UK Limited","startDate":"2018-09-17","conditions":"Deep Vein Thrombosis, Atrial Fibrillation, Post-Myocardial Infarction Syndrome","enrollment":420},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT03573037","phase":"NA","title":"Anticoagulation After RFCA","status":"UNKNOWN","sponsor":"Yong Seog Oh","startDate":"2014-07","conditions":"Atrial Fibrillation","enrollment":246},{"nctId":"NCT03462446","phase":"","title":"Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-01","conditions":"Atrial Fibrillation","enrollment":249},{"nctId":"NCT02611635","phase":"","title":"Atrial Fibrillation Patient Preference Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-02","conditions":"Atrial Fibrillation","enrollment":382},{"nctId":"NCT00559988","phase":"PHASE4","title":"Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk","status":"TERMINATED","sponsor":"Biotronik, Inc.","startDate":"2008-02","conditions":"Atrial Fibrillation, Atrial Flutter, Stroke","enrollment":2718},{"nctId":"NCT02227550","phase":"PHASE4","title":"Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy","status":"COMPLETED","sponsor":"Atrial Fibrillation Network","startDate":"2014-12","conditions":"Atrial Fibrillation","enrollment":676},{"nctId":"NCT01727453","phase":"PHASE4","title":"Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-12","conditions":"Acute Gastrointestinal Bleeding","enrollment":40},{"nctId":"NCT01674647","phase":"PHASE3","title":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":"Atrial Fibrillation","enrollment":1504},{"nctId":"NCT00645853","phase":"PHASE2","title":"Long-term Safety in Atrial Fibrillation Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Persistent or Permanent Nonvalvular Atrial Fibrillation","enrollment":523},{"nctId":"NCT00062803","phase":"PHASE3","title":"SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Pulmonary Embolism","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Warfarin VKA","genericName":"Warfarin VKA","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and preventing blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) treatment and prevention, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}